Capstone Asset Management’s Ligand Pharmaceuticals LGND Stock Holding History

Capstone Asset Management’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$341K	Buy	4,509 +160	+4%	+$11.2K	0.01%	1156
2017 Q1	$287K	Buy	4,349 +192	+5%	+$12.6K	0.01%	1324
2016 Q4	$263K	Sell	4,157 -3,398	-45%	-$214K	0.01%	1405
2016 Q3	$481K	Sell	7,555 -353	-4%	-$25.9K	0.01%	982
2016 Q2	$588K	Buy	7,908 +1,812	+30%	+$134K	0.02%	823
2016 Q1	$407K	Buy	6,096 +368	+6%	+$22.4K	0.01%	1051
2015 Q4	$387K	Buy	5,728 +1,390	+32%	+$85.8K	0.01%	1094
2015 Q3	$232K	Buy	4,338 +161	+4%	+$9.77K	0.01%	1399
2015 Q2	$263K	Sell	4,177 -797	-16%	-$43.5K	0.01%	1375
2015 Q1	$239K	Buy	+4,974	New	+$191K	0.01%	1503
2014 Q3	–	Sell	-5,375	Closed	-$209K	–	1660
2014 Q2	$209K	Sell	5,375 -229	-4%	-$9.29K	0.01%	1569
2014 Q1	$235K	Sell	5,604 -4,985	-47%	-$208K	0.01%	1568
2013 Q4	$347K	Buy	+10,589	New	+$345K	0.01%	1409

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Capstone Asset Management's LGND Position: Q2 2017 in Review

Capstone Asset Management increased its Ligand Pharmaceuticals (LGND) stake by 3.7% in Q2 2017, buying an estimated $11.2K and bringing the position to 4,509 shares worth $341K. The position accounts for 0.01% of the portfolio, ranked #1156.

Capstone Asset Management first reported a position in LGND in Q4 2013 and has held it in 13 quarters since. The position peaked at $588K in Q2 2016. 265 funds tracked by Wall St. Rank hold LGND as of Q2 2017.

Capstone Asset Management held 4,509 shares of Ligand Pharmaceuticals worth $341K as of Q2 2017.
Capstone Asset Management bought 160 Ligand Pharmaceuticals shares in Q2 2017, an estimated $11.2K.
Ligand Pharmaceuticals made up 0.01% of Capstone Asset Management's portfolio in Q2 2017, its #1156 holding.
Capstone Asset Management first reported a position in Ligand Pharmaceuticals in Q4 2013 and has held it in 13 quarters since.
Capstone Asset Management's Ligand Pharmaceuticals position peaked at $588K in Q2 2016.
265 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.